OBJECTIVES:Capparis spinosa L. (Caper) fruit is traditionally used as an anti-hyperglycemic food by Iranian diabetic patients. But yet, no controlled human study has determined its efficacy in treatment of hyperglycemia in type 2 diabetic patients. DESIGN: The present study was undertaken to explore the possible anti-hyperglycemic effects of the caper fruit extract in type 2 diabetic patients. A randomized clinical trial was conducted in 54 type 2 diabetic patients. Two groups 28 and 26 patients on standard anti-diabetic therapy, received 400mg caper fruit extract and placebo capsules three times a day respectively for two months. MAIN OUTCOME MEASURES: The patients fasting blood glucose, glycosylated hemoglobin, lipids levels, liver and renal function tests were determined at baseline and endpoint. RESULTS: Results showed significant decrease in fasting blood glucose levels (p=0.037) and glycosylated hemoglobin (p=0.043) in caper treated patients compared to control group at the end of the study. Triglyceride level also decreased significantly (p=0.29) in caper treated group at the end of the study compared to baseline. No liver, kidney and other side effects were observed in these two groups. CONCLUSIONS:Caper fruit extract may be a safe anti-hyperglycemic and anti-hypertriglyceridemic agent for type 2 diabetic patients.
RCT Entities:
OBJECTIVES:Capparis spinosa L. (Caper) fruit is traditionally used as an anti-hyperglycemic food by Iranian diabeticpatients. But yet, no controlled human study has determined its efficacy in treatment of hyperglycemia in type 2 diabeticpatients. DESIGN: The present study was undertaken to explore the possible anti-hyperglycemic effects of the caper fruit extract in type 2 diabeticpatients. A randomized clinical trial was conducted in 54 type 2 diabeticpatients. Two groups 28 and 26 patients on standard anti-diabetic therapy, received 400mg caper fruit extract and placebo capsules three times a day respectively for two months. MAIN OUTCOME MEASURES: The patients fasting blood glucose, glycosylated hemoglobin, lipids levels, liver and renal function tests were determined at baseline and endpoint. RESULTS: Results showed significant decrease in fasting blood glucose levels (p=0.037) and glycosylated hemoglobin (p=0.043) in caper treated patients compared to control group at the end of the study. Triglyceride level also decreased significantly (p=0.29) in caper treated group at the end of the study compared to baseline. No liver, kidney and other side effects were observed in these two groups. CONCLUSIONS:Caper fruit extract may be a safe anti-hyperglycemic and anti-hypertriglyceridemic agent for type 2 diabeticpatients.
Authors: Kaushik Chattopadhyay; Haiquan Wang; Jaspreet Kaur; Gamze Nalbant; Abdullah Almaqhawi; Burak Kundakci; Jeemon Panniyammakal; Michael Heinrich; Sarah Anne Lewis; Sheila Margaret Greenfield; Nikhil Tandon; Tuhin Kanti Biswas; Sanjay Kinra; Jo Leonardi-Bee Journal: Front Pharmacol Date: 2022-06-08 Impact factor: 5.988